Niclosamide In Moderate COVID-19

Summary

This is a Phase 2, multicentre, randomized, double blind, 2 arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms.

Timeline

Start

2022-01-20

Primary completion

2022-01-20

Completion

2022-01-20

Outcome

Outcome not reported

Stopped: “Sponsor asset acquired by another pharma company who opened their own IND for this compound. First Wave Bio never started this study in the US or ex-US.”

Drugs

Indications